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Alternative Treatment with Red Yeast Rice to Reduce Hyperlipidemia
Lisa Froemke, PA-S
Physician Assistant Program, University of North Dakota School of Medicine & Health Sciences

Abstract
• First line treatment of cardiovascular disease is lifestyle modification
followed by the pharmacologic intervention of HMG-CoA reductase
inhibitors or statins

Literature Review
PATHOPHYSIOLOGY OF HYPERLIPIDEMIA

• RYR preparations claim to inhibit cholesterol synthesis without causing
myalgia

• Excess lipids form plaque in the arteries reducing blood flow (See Figure 4)
• LDL cholesterol transfers cholesterol to cells in tissues and is equal to the risk of
atherosclerosis in predicting coronary disease (Papadakis, Tierney, & McPhee,
2011)
• HDL cholesterol transfers cholesterol from the cells in tissues to be eliminated
and is inversely equal to the risk of atherosclerosis (Papadakis et al., 2011)

• RYR preparations have naturally occurring monacolins such as monacolin K
which is chemically identical to lovastatin

• 11.5 years of life is projected to be lost in consequence to the development
of atherosclerosis leading to coronary heart disease (Sikka et al., 2011).

• Statins are commonly associated with intolerable side effects such as
myalgia leading to medication non-compliance

• RYR is not regulated by the FDA leading to questionable manufacturing
practices producing varying ingredient composition
• The purpose of this study is to investigate the role RYR in hyperlipidemia
treatment compared to statins by evaluating efficacy, side effects, and the
potential to reduce medication non-compliance in adults
• Clinicians potentially could recommend RYR as an alternative treatment to
hyperlipidemia in patients unable to comply with statin treatment to
decrease cholesterol levels and reduce the progression of atherosclerosis

Introduction
• Statins reduce lipid levels when lifestyle modifications are not adequate
• Potential adverse effects of statins include myalgia and rhabdomyolysis
• Non-compliance increases the risk of further atherosclerosis formation
potentially leading to cardiovascular disease and related events
• RYR has been utilized in China since the Tang Dynasty in 800 AD
• Over the counter RYR has flourished in popularity with claims of being a
natural product formed from cultured Monascus purpureus yeast on rice
(See Figure 1), conveniently ordered online, and costing less than
prescription statins
• Clinicians desire alternative treatment options for patients to reduce noncompliance that are effective and safe to reduce lipid levels and slow the
progression of atherosclerosis

Statement of the Problem

TREATMENT OPTIONS FOR HYPERLIPIDEMIA
• Statin and RYR have similar pathophysiology due to sharing the same active
ingredient, monacolin
• MOA: Interfere with the conversion of Acetyl CoA to Mevalonate by inhibiting
the enzyme HMG-CoA reductase (See Figure 2) (Verhoeven et al., 2013)
• RYR comes in variations that do not have equal potency due to varying active
potentials just as statins do not have equal potency when compared to each other
(Musselman, Pettit, & Derenski, 2012)
Acetyl CoA
↓
HMG-CoA
RYR or Statins (Monacolins)→ ↓ ←HMG-CoA Reductase (Inhibited)
Mevalonate
↓
Cholesterol
– Figure 2: Adapted from Applied Pharmacology by Bardal, Waechter, & Martin,
2011 reflecting the effects of stains and RYR on cholesterol biosynthesis

Research Question
• In patients with hyperlipidemia does RYR supplement as compared to statin
treatment provide efficacious hypolipidemic results?

 Verhoeven et al. (2013) proposed less patient non-compliance with RYR
due to reduced monthly cost of RYR $20-30 vs statins $120-300


Becker et al. (2013) reported 40% statin discontinuation within first year
due to fear of adverse effects, cost, and reluctance to take medication
chronically

 Becker et al. (2009) trial demonstrated RYR had a significant reduction in
LDL and total cholesterol when compared to placebo without increased
myalgia making RYR a potential treatment option

• Three trials involving prescription statin intervention reflected a reduction in
coronary events by 23-34% and coronary heart disease mortality by 20-42%
(Yang & Mousa, 2012)
• Becker et al. (2008) compared RYR to simvastatin reflecting significant LDL
reduction without significant differentiation between test groups
• Halbert et al. (2010) compared tolerability of pravastatin to RYR without
significant difference in LDL reduction between test groups

STATINS VS RYR SIDE EFFECTS
• Statins are generally well tolerated, possible side effects include: myalgia,
myositis, rhabdomyolysis, and hepatoxicity with 10-15% of statin users
developing myalgias (Bardal et al., 2011)
• 57% statin users experience myalgias when trying a second statin (Abd &
Jacobson, 2011)
• RYR side effects include: dizziness, decreased appetite, nausea, abdominal pain,
distension, and diarrhea occurring in 1.3-36% of patients (Liu et al., 2006)
• Halbert et al. (2010) compared tolerability of pravastatin to RYR with 67% in
RYR group reporting pain and 68% in the pravastatin group therefore similar
tolerability
• Heber et al. (2001) analyzed 9 different commercially available RYR products
and discovered varying monacolin content from 0-0.58% and toxic citrinin
byproduct in 7 out of 9 preparations
• No studies are available regarding long-term cardiovascular prevention with RYR
as with statin use
• Statin safety concern addressed by the FDA ten years ago involved Bayer
removing the statin, cerivastatin, after 31 patients died from rhabdomyolysis
(Bardal et al., 2011)
• Between 1987 and 2001 the FDA recorded 42 deaths or one death per million 30day supply prescriptions of statins from rhabdomyolysis (Sikka et al., 2011)

Applicability to Clinical
Practice
 RYR has potential to reduce hyperlipidemia as reflected in short
duration trials but at this time can not be recommended due to lack of
standardization, long-term side effects, narrow test populations, and
secondary cardiovascular prevention
 RYR is not practical in healthcare setting due to lack of FDA
regulation allowing for varying amounts of monacolin and potential
toxic citrinin byproduct
 Current FDA approved pharmacologic lipid modifying agents include niacin
(vitamin B5), bile acid sequestrants, HMG-CoA reductase inhibitors,
fibrates, and Ezetimibe with each group of agents having a unique
mechanism of action to prevent further atherosclerosis (See Figure 4)

 Halbert et al. (2010) trial reflected RYR and pravastatin were tolerated
equally with both groups experiencing recurrent myalgia and achieving
comparable LDL cholesterol values therefore not supporting RYR as an
alternative option
 The meta-analysis conducted by Liu et al. (2006) evaluated RYR
supplements (Cholestin, Xuezhikang, and Zhibituo) vs placebo. reflecting
the three RYR variations significantly reducing total cholesterol levels
compared when compared to placebo over a 12 week duration (See Figure
3)
 Figure 4: Atherosclerosis
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• RYR was compared to placebos such as the American Heart Step 1 Diet,
phytosterol tablets, lifestyle changes, fish oil with all trials resulting in the
reduction of total and LDL cholesterol that was superior or equal to placebo
• The meta-analysis conducted by Liu et al. (2006) evaluated 93 randomized trials
consisting of 9,625 participants utilizing three different variations of RYR
preparations, Cholestin, Xuezhikang, and Zhibituo, with treatment duration
ranging from 4 to 24 weeks with all 3 variations of RYR significantly reducing
total cholesterol

STATINS VS RYR SAFETY
• Figure 1: Red Yeast Rice

 Childress et al. (2013) summarized RYR utilization has increased in
popularity exponentially due the public’s perception of RYR being
“natural” compared to prescription medication, perceived less side effects
such as myalgia, reduced cost, over the counter availability, and lack of
drug-drug interactions

EFFICACY OF RYR THERAPY

EFFICACY OF STATINS VS RYR
• Studies are needed to determine if RYR supplement in the treatment of
hyperlipidemia is a comparable treatment option to statins in efficacy, side
effects, and safety to potentially reduce medication non-compliance.

Discussion

– Figure 3: RYR supplements (Cholestin, Xuezhikang, and Zhibituo) vs
placebo. Adapted from “Chinese Medicine” (2006), Retrieved from:
http://www.cmjournal.org/content/1/1/4 reflecting RYR significantly
reducing total cholesterol levels
 When 101 products containing RYR were reviewed none could be
confirmed as passing any independent laboratory verification testing
necessary to promote consistent composition of the active ingredient,
monacolin, and no possible toxic byproducts including citrinin (Childress
et al., 2013)
 RYR supplements are not strictly regulated by the FDA due to being
considered a food not a drug therefore side effects are not documented as
systematically as prescription medications such as statins
 Halbert et al. (2010) and Becker et al. (2009) highlight various RYR
potency, unsupervised availability, and possible contamination with citrinin
due to lack of consistency between different manufacturers supporting
RYR is not safe for the general public’s consumption
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